MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Prothena Corp PLC

Suletud

SektorTervishoid

9.63 0.73

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

9.41

Max

9.96

Põhinäitajad

By Trading Economics

Sissetulek

1M

-58M

Müük

1.2M

2.1M

Aktsiakasum

-1.08

Kasumimarginaal

-2,729.911

Töötajad

163

EBITDA

1.6M

-65M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+465.49% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. mai 2025

Turustatistika

By TradingEconomics

Turukapital

-264M

501M

Eelmine avamishind

8.9

Eelmine sulgemishind

9.63

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

Prothena Corp PLC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

28. mai 2024, 22:51 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Bristol Myers Squibb Adds to Neurodegenerative Treatment Investments -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Prothena Corp PLC Prognoos

Hinnasiht

By TipRanks

465.49% tõus

12 kuu keskmine prognoos

Keskmine 54.57 USD  465.49%

Kõrge 110 USD

Madal 20 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Prothena Corp PLC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

6

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

9.585 / 10.07Toetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Strong Bearish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Prothena Corp PLC

Prothena Corporation PLC is a late-stage clinical company. The Company is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. It is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The Company's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aß) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.